
Please try another search
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Andrew John McGlashan Richards | 61 | 2016 | Non-Executive Chairman |
Christine Helen Soden | 67 | 2021 | Independent Non-Executive Director |
Jeremy Lewis Morgan | 61 | 2021 | Independent Non-Executive Director |
Sarah Jennifer Howell | 50 | 2011 | CEO & Executive Director |
Mohammad Sohail Fazeli | 61 | 2017 | Independent Non-Executive Director |
Eda Cengiz | - | 2017 | Member of Global Diabetes Scientific Advisory Board |
Thomas R. Pieber | - | 2017 | Member of Global Diabetes Scientific Advisory Board |
Bruce Buckingham | - | 2017 | Member of Global Diabetes Scientific Advisory Board |
David Brayden | - | 2025 | Member of Scientific Advisory Board |
Randall Mrsny | 70 | 2025 | Member of Scientific Advisory Board |
Christopher Porter | - | 2025 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review